NCT03242382 2024-01-23
PalboSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 2 Unknown
Clinical Trials
16 trialsNCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT04334330 2022-05-02
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03633331 2021-10-15
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT05076695 2021-10-13
NeoTPPF
Fudan University
Phase 2 Unknown
NCT04858997 2021-07-15
Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT04247633 2020-04-20
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
Samsung Medical Center
Phase 2 Unknown
NCT04318223 2020-03-23
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
Consorzio Oncotech
Phase 2 Unknown
NCT02690480 2020-02-05
FLIPPER
Spanish Breast Cancer Research Group
Phase 2 Unknown
NCT02592746 2019-04-08
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
Phase 2 Unknown
NCT03560856 2018-06-18
PALPETBIO
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03454919 2018-03-06
Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03219554 2017-08-02
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
Samsung Medical Center
Phase 2 Unknown
NCT01709370 2013-12-31
Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women
Organisation for Oncology and Translational Research
Phase 2 Unknown